About our Policy
GlycoMimetics is committed to advancing research and providing hope for people living with diseases with high unmet need. A key component in finding new treatments for diseases such as acute myeloid leukemia (AML) and multiple myeloma (MM) is the design and execution of clinical trials to test the safety and efficacy of potential drug candidates.
Currently, there are several clinical trials of GlycoMimetics’ drug candidates underway and these trials are being conducted with very limited drug supply. As a result, GlycoMimetics anticipates limited opportunities to provide drugs to patients requesting expanded access due to the need to prioritize use of the drug candidates in on-going clinical trials.
Expanded Access Requests
GlycoMimetics considers expanded access requests on a case-by-case basis. Consideration factors include: the patient’s ability and eligibility to participate in an ongoing trial, drug supply and availability, the treating physician’s benefit-to-risk analysis, and institutional experience with the drug, among others.
For More Information
U.S. based providers or treating physicians should fill out the information request form below and will be contacted within 7 business days to schedule a consultation. This form does not serve as an expanded access request. After the initial consultation, providers will receive additional guidance if they are interested in submitting a formal request.